Additional Information
Description
Biktarvy® is a fixed-dose combination tablet containing bictegravir sodium (50 mg), emtricitabine (200 mg), and tenofovir alafenamide fumarate (25 mg). This medication is used for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg. It combines a nucleotide reverse transcriptase inhibitor (NRTI) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) with an integrase strand transfer inhibitor (INSTI).
Bictegravir inhibits the integrase enzyme, preventing integration of viral DNA into the host genome. Emtricitabine and tenofovir alafenamide are NRTIs that block viral reverse transcription and replication. The combination of these three drugs offers a potent regimen with a low risk of resistance, making it suitable for treatment-naïve individuals.
Common side effects of Biktarvy® include headache, diarrhea, nausea, and fatigue. Serious adverse effects may include liver problems, kidney dysfunction, and the development of drug resistance if the regimen is not followed correctly. Regular monitoring of renal and liver function is recommended.
B
You've just added this product to thecart: